中华预防医学会血液病预防专业委员会 常务委员
Standing Committee Member, Hematopathy Prevention Committee, Chinese Preventive Medicine Association
中国抗癌协会淋巴瘤专业委员会 委员
Member, Lymphoma Committee, Chinese Anti-Cancer Association
中国免疫学会血液免疫分会专业委员会 委员
Member, Professional Committee of Hematological Immunology, Chinese Society for Immunology
中国研究型医院学会生物治疗学专业委员会 委员
Member, Biotherapy Committee, Chinese Research Hospital Association
中国血液科专科联盟白血病免疫细胞治疗协作组 副组长
Deputy Group Leader, Leukemia Immune Cell Therapy Collaboration Group, Chinese Hematology Specialty Alliance
中华志愿者协会中西医结合专委会血液科专业组 副组长
Deputy Group Leader, Hematology Specialty Group, Committee of Integrated Traditional Chinese and Western Medicine, Chinese Volunteers Association
近十年来致力于血液肿瘤的嵌合抗原受体（CAR）-T细胞治疗的基础和临床研究，本研究团队首次建立基于DLBCL患者基线特征和影像学特征的CAR-T预后预测模型 (CMJ，2024；Cancer Med，2024)；在国际上首次提出“表观免疫调节治疗”理念，并在2022年Cancer Commun (Lond)杂志发表。在CAR-T治疗毒性管理和全程管理方面积累了相当丰富的临床经验，迄今为止已成功CAR-T治疗患者达5百例。2022年牵头撰写的《CAR-T细胞治疗淋巴瘤毒性管理中国专家共识》并发表于Cancer Biol Med杂志。至今发表SCI和核心杂志共50余篇，其中以第一作者或通讯作者发表20余篇。先后主持3项国家自然科学基金项目（No. 31301118；82070168；82470225），作为学术骨干参与科技部国家重点研发计划重点专项项目1项（2021YFA1100800）和国家自然科学基金重点项目1项（81830004）。主持《促进市级医院临床技能与临床创新三年行动计划》研究型医师创新转化能力培训项目1项（SHDC2023CRD021）。《血液系统恶性肿瘤细胞治疗的体系创新和临床应用》项目获2024年度上海医学科技奖一等奖；2025年被评为 “同医最美科技工作者”。
Over the past decade, the research team has been dedicated to basic and clinical research on chimeric antigen receptor (CAR)-T cell therapy for hematological malignancies. The team established for the first time internationally a CAR-T prognostic prediction model based on baseline clinical characteristics and imaging features of patients with diffuse large B-cell lymphoma (DLBCL) (published in Chinese Medical Journal, 2024; Cancer Medicine, 2024). It also pioneered the novel concept of epigenetic immunomodulatory therapy globally, which was published in Cancer Communications (Lond) in 2022.
The team has accumulated extensive clinical experience in the toxicity management and whole-course standardized management of CAR-T therapy. To date, more than 500 patients have been successfully treated with CAR-T cell therapy. In 2022, the team led the formulation and publication of the Chinese Expert Consensus on Toxicity Management of CAR-T Cell Therapy for Lymphoma in Cancer Biology & Medicine.
Up to now, the team has published over 50 papers in SCI-indexed journals and core domestic journals, among which more than 20 were published as the first author or corresponding author. The principal investigator has presided over 3 National Natural Science Foundation of China (NSFC) projects (Grant Nos. 31301118, 82070168, 82470225). As a key academic member, the investigator participated in 1 Key Special Project of the National Key R&D Program of the Ministry of Science and Technology (2021YFA1100800) and 1 Key Project of the National Natural Science Foundation of China (81830004). Additionally, the investigator undertakes one training project for innovative transformation capacity of research-oriented physicians under the Three-Year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals (SHDC2023CRD021).
The project System Innovation and Clinical Application of Cellular Therapy for Hematological Malignancies was awarded the First Prize of the 2024 Shanghai Medical Science and Technology Award. In 2025, the investigator was honored as one of the "Most Outstanding Scientific and Technological Workers of Tongji Medical Affiliated Institutions"
